The presentation highlighted tolebrutinib’s potential as the first Bruton's tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the ...

No writing assistance was utilized in the production of this manuscript. Tyrosine kinase inhibitors (TKIs) are used for the targeted treatment of cancer. TKIs produce a range of serious adverse ...

School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China ...

Here we studied the role of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling in the pathogenesis of collagen-induced arthritis (CIA). Methods CIA was induced in mice lacking Flt3L (Flt3L −/−) and ...

who are being treated with Bruton Tyrosine Kinase inhibitors (BTKi), should continue their therapy while receiving COVID-19 vaccination. The IMPROVE study investigated whether a three-week pause ...

“Pirtobrutinib has added an entire line of therapy for patients with progression on covalent BTK [Bruton’s tyrosine kinase] inhibitors and venetoclax,” said Hematologist-Oncologist Jennifer ...

The White House appeared to revel in its cruelty when it used an AI-created cartoon to mock a Dominican migrant who was detained by ICE earlier this month. No one suspected the White House would jump ...

Given the sheer diversity of kinases and their inhibitors, this article will break down the major categories, highlight breakthrough therapies, and spotlight the exciting innovations shaping the next ...

Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely ...

1-4 The investigational, orally administered Bruton’s tyrosine kinase inhibitor was developed to target smoldering neuroinflammation, which is among the primary drivers of disability progression in ...

Wojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders. Wojciech Jurczak, MD, PhD, head of the department of ...